Short Interest in Capstone Therapeutics Corp. (NASDAQ:CAPS) Rises By 170.3%

Capstone Therapeutics Corp. (NASDAQ:CAPS) was the target of a large growth in short interest during the month of April. As of April 30th, there was short interest totaling 199,019 shares, a growth of 170.3% from the April 15th total of 73,622 shares. Based on an average daily volume of 9,855,381 shares, the short-interest ratio is presently 0.0 days. Approximately 2.3% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Capstone Therapeutics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Capstone Therapeutics

A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC acquired a new stake in Capstone Therapeutics Corp. (NASDAQ:CAPS) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned 1.51% of Capstone Therapeutics at the end of the most recent quarter. Institutional investors own 2.55% of the company’s stock.

Capstone Therapeutics Trading Down 5.0%

CAPS stock opened at $0.28 on Friday. Capstone Therapeutics has a 1-year low of $0.26 and a 1-year high of $3.29. The firm has a market cap of $4.06 million, a P/E ratio of -0.08 and a beta of -1.52. The business’s 50 day moving average is $0.53 and its 200-day moving average is $0.68. The company has a current ratio of 1.00, a quick ratio of 0.26 and a debt-to-equity ratio of 0.75.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.